31 results about "CD5" patented technology

The present disclosure provides chimeric antigen receptor polypeptides having antigen recognition domains for CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens, and polynucleotides encoding for the same. The present disclosure also provides for engineered cells expressing the polynucleotide or polypeptides. In some embodiments, the disclosure provides methods for treating diseases associated with CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens.

The present invention relates to the field of compositions comprising anti-CD5 antibodies. In particular, the present invention concerns an antibody composition comprising at least two anti-CD5 antibodies capable of binding distinct CD5 epitopes. The invention further concerns bi-specific molecules having the binding specificities of said antibody compositions. The invention also relates topharmaceutical compositions, use of antibody compositions and methods for manufacturing antibody compositions. The invention further relates to cell banks and a method for killing cells.

The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of these IL-10 producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, and / or to treat tumors / cancer. Diagnostic applications also are encompassed.

The present invention discloses soluble isoforms of CD5 and CD6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and / or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin. The invention also provides animal models for the study and the prophylaxis / treatment of autoimmune diseases, cancer, and chronic infections.

The invention relates to a CAR-NK cell as well as a preparation method and application thereof. The invention firstly provides a bispecific chimeric antigen receptor targeting BCMA and CD5, the bispecific chimeric antigen receptor has the following structure: S-BCMA scFv-CD5scFv-H-TM-CF-CD3zeta, the BCMA scFv is a BCMA antigen binding domain, the BCMA scFv-CD5scFv-H-TM-CF-CD3zeta is a BCMA antigen binding domain, and the BCMA The CD5 scFv is a CD5 antigen binding domain; s is a signal peptide; h is a hinge area; tM is a transmembrane area; cF is a costimulatory factor; cD3zeta is a CD3zeta intracellular signal domain, the chimeric antigen receptor can be combined with two anti-tumor targets, namely BCMA and CD5 at the same time, and the targeting property and effectiveness can be remarkably improved; by knockout of immune checkpoint inhibitor genes in NK cells, it is possible to prevent tumor cells from triggering immune escape through specific binding with related immune checkpoint inhibitor sites, and experimental data proves that CTLA4 is selected as a knockout immune checkpoint and has more advantages compared with other immune checkpoint genes such as PD-1, Tim-3 and LAG-3. The chimeric antigen receptor is introduced into an NK cell to prepare a CAR-NK cell, and the CAR-NK cell can inhibit leukemia cell proliferation, regulate expression levels of cell factors such as IL-6, IL-12 and IFN-gamma, inhibit growth of tumors in an animal model and play a synergistic anti-tumor role.

The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells, wherein CD2, CD5, or CD7 has been knocked-out.

The present disclosure provides chimeric antigen receptor polypeptides having antigen recognition domains for CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens, and polynucleotides encoding for the same. The present disclosure also provides for engineered cells expressing the polynucleotide or polypeptides. In some embodiments, the disclosure provides methods for treating diseases associated with CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens.

Embodiments of the disclosure include methods and compositions related to immunotherapy that targets CD5. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor (CAR) that targets CD5 are contemplated, and uses thereof. In particular embodiments, the immune cells expressing the CAR do not commit fratricide to any great extent against T cells that express CD5 and which are endogenous to an individual receiving the immune cells.

The present invention discloses soluble isoforms of CD5 and CD6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and / or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin. The invention also provides animal models for the study and the prophylaxis / treatment of autoimmune diseases, cancer, and chronic infections.

The invention discloses a human T-lymphoblastic leukemia / lymphoma cell line and its construction method and application. The human T-lymphoblastic leukemia / lymphoma cell line is named as human T-lymphoblastic leukemia / lymphoma ZYXY-T1, and was deposited in the China Center for Type Culture Collection (Wuhan University, Wuhan, China) on January 20, 2021, with a deposit number It is CCTCC NO:C202143. The present invention is obtained by extracting and separating mononuclear cells from the peripheral blood of clinical human T-lymphoblastic leukemia / lymphoma patients, and culturing them in vitro for continuous natural passage. This leukemia cell line has the typical surface antigen expression characteristics of ETP‑ALL, that is, it does not express CD1α, CD5, CD8, highly expresses the stemness marker CD34, has good in vitro proliferation ability and in vivo tumorigenesis ability, and can be used as a study on the development mechanism of ETP‑ALL Research and individualized treatment In vitro research cell materials can also be used for in vivo and in vitro research ETP‑ALL drug screening, evaluation, and guidance for clinical medication.

The present invention refers to a method of predicting response of a human subject to Interferon beta, (IFN-β), wherein the subject is suffering from Multiple Sclerosis (MS), and wherein the method comprises using, as an indicator, the percentage of CD5+ CD19+ CD45+ B cells over the total count of lymphocytes (CD45+ cells) in a biological sample originating from the human subject and the percentage of CD8+ CD45+ perforin+ T cells over the total count of lymphocytes (CD45+ cells) in a biological sample originating from the human subject, wherein if the percentage of CD5+ CD19+ CD45+ B cells over the total count of lymphocytes (CD45+ cells) is lower than or equal to 3% and / orthe percentage of CD8+ CD45+ perforin+ T cells over the total count of lymphocytes (CD45+ cells) is greater than or equal to 1%, is indicative of response.

The invention relates to a combined reagent and system for detecting acute myeloid leukemia cells, belonging to the technical field of medicine. The combination reagent includes at least one of the following antibody combinations: antibody combination 1, including CD38, CD13, CD34, CD117, CD33, CD19, HLA‑DR and CD45 antibodies; antibody combination 2, including CD38, CD64, CD34, CD123 , CD56, CD14, HLA‑DR, and CD45 antibodies; antibody panel 3: includes CD38, CD7, CD34, CD5, CD11b, CD15, and CD45 antibodies. The antibody combination of the present invention covers the expression markers of three lineages of granulocystosis, monocystosis and lymphoma, and with the establishment of a normal antibody expression pattern, it can identify tumor cells to the greatest extent. Moreover, a large amount of experimental data shows that there is no problem of mutual inhibition of expression among the antibodies in each combination of the present invention. AML‑MRD can be detected comprehensively, quickly and with high sensitivity through multiparameter flow cytometry analysis.

The invention provides anti-CD5 antibodies, antigen-binding fragments thereof, and antibody drug conjugates thereof, for use in treating, for example, a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. Compositions and methods for depleting populations of CD5+ cells, such as CD5+ cancer cells and CD5+ immune cells are described, and can be used to treat cancers and autoimmune diseases directly as stand-alone therapies by eradicating cancerous cells and autoreactive immune cells that express CD5 and / or to prepare a patient for hematopoietic stem cell transplantation, for instance, by depleting populations of CD5+ immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cells.

The present disclosure provides for methods and compositions for the modulation of CD5 in a subject. Also provided are methods of detecting and monitoring diseases, such as inflammatory and autoimmune diseases.

The invention relates to a monoclonal antibody capable of recognizing human CD5 antigen, a secreting cell line, its preparation method and its application in immunoassay. The above technical scheme selects the 398th to 495th amino acid at the C-terminus of the CD5 protein as the antigenic peptide, and performs codon optimization to become a gene fragment suitable for expression in Escherichia coli BL21. The resulting recombinant protein contains the CD5 protein fragment and histidine protein tag. The recombinant protein is used to immunize mice, and through cell fusion, screening and subcloning, the mouse hybridoma cell line 11H3 that efficiently secretes anti-CD5 protein monoclonal antibody, and the anti-CD5 protein monoclonal antibody secreted by the cell line are obtained Antibody. The antibody obtained by this protocol has high specificity and sensitivity, can specifically recognize cells expressing CD5 protein, and is suitable for immunological detection, especially immunohistochemical detection.

The present invention provides a nucleic acid molecule encoding a chimeric antigen receptor targeting CD5, the chimeric antigen receptor comprises an extracellular region, a transmembrane region and an intracellular signal transduction region, the extracellular region encoded by it The region comprises a CD5 binding domain, and the CD5 binding domain is the amino acid sequence shown in SEQ ID NO.3. The cytokines secreted by NK cells were detected by flow cytometry, degranulation analysis experiments, and ELISA, which proved that the CD5 CAR NK cells had a strong killing effect on blood tumor cells expressing CD5, but had a strong killing effect on cells that did not express CD5. Weak, effectively preventing off-target effects. The chimeric antigen receptor CD5 scFv-CD8α-4-1BB-CD3ζ of the present invention can be used for the treatment of CD5-positive lymphocytic blood tumors.

The invention relates to a combined reagent and system for evaluating the prognosis of chronic lymphocytic leukemia, belonging to the field of medical technology detection. The combination reagent includes at least one of the following antibody combinations: antibody combination 1, including CD5, IgG1, CD3, CD19 and CD45 antibodies; antibody combination 2, including CD5, ZAP70, CD3, CD19 and CD45 antibodies; antibody combination 3: Includes CD38, CD49d, CD19, CD5, and CD45 antibodies. Among the above-mentioned antibody combinations against CLL of the present invention, the expressions of ZAP70, CD38, and CD49d are of great value in evaluating prognosis, and ZAP70 is one of the more accurate ones, but its clinical application is limited due to intracellular staining and gating techniques, and this The invention solves this problem to the greatest extent. In addition, two indicators are added. Combining these markers can provide a more comprehensive assessment of the prognosis of chronic lymphocytic leukemia.